Edition:
United Kingdom

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

4.66USD
18 Oct 2018
Change (% chg)

-- (--)
Prev Close
$4.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
124,703
52-wk High
$7.94
52-wk Low
$3.23

Chart for

About

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active... (more)

Overall

Beta: 1.29
Market Cap(Mil.): $174.93
Shares Outstanding(Mil.): 30.00
Dividend: --
Yield (%): --

Financials

  CNAT.OQ Industry Sector
P/E (TTM): -- 85.68 33.65
EPS (TTM): -0.99 -- --
ROI: -53.65 0.45 14.28
ROE: -80.58 1.37 16.00

BRIEF-Conatus Pharmaceuticals Q1 Revenue $9.7 Million

* CONATUS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROGRAM UPDATES

02 May 2018

Competitors

  Price Chg
BASF SE (BASFn.DE) €67.65 -0.53
Johnson & Johnson (JNJ.N) $139.05 -0.45
Novartis AG (NOVN.S) CHF87.04 +1.16
Merck & Co., Inc. (MRK.N) $72.35 +0.14
Roche Holding Ltd. (ROG.S) CHF244.95 +6.40
Roche Holding Ltd. (RO.S) CHF245.20 +5.80

Earnings vs. Estimates